Ampersand Capital’s Investment in P95

Quinz advised Ampersand Capital on its investment. P95 BV, a global provider of epidemiology and clinical research solutions focused on vaccines and infectious diseases, has announced...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here